{"transactions":[{"id":979198,"issuer":{"id":72153,"kind":"organization","name":"Mural Oncology plc","symbol":"MURA"},"owners":[{"id":72155,"kind":"person","name":"Goodman Vicki L","position":1,"cik":"0001901477","reported_name":"Goodman Vicki L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (right to buy)","published_at":"2025-12-05T08:45:53.000Z","date":"2025-12-05","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":65000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the terms of the Agreement, at the Effective Time each option to purchase ordinary shares of Issuer that had an exercise price per share that was equal to or greater than the Scheme Consideration was cancelled and ceased to be outstanding, and no Scheme Consideration was delivered in exchange for such options."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Pursuant to the terms of the Agreement, at the Effective Time each option to purchase ordinary shares of Issuer that had an exercise price per share that was equal to or greater than the Scheme Consideration was cancelled and ceased to be outstanding, and no Scheme Consideration was delivered in exchange for such options."}],"balance_after":0,"derivative":{"exercise_price":3.43,"expiration_date":"2035-03-02","underlying":"Ordinary Shares","underlying_shares":65000},"source":{"system":"sec-edgar","filing":"0001193125-25-308745","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1971543/000119312525308745/ownership.xml","form_type":"4"}},{"id":979197,"issuer":{"id":72153,"kind":"organization","name":"Mural Oncology plc","symbol":"MURA"},"owners":[{"id":72155,"kind":"person","name":"Goodman Vicki L","position":1,"cik":"0001901477","reported_name":"Goodman Vicki L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (right to buy)","published_at":"2025-12-05T08:45:53.000Z","date":"2025-12-05","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":135604,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the terms of the Agreement, at the Effective Time each option to purchase ordinary shares of Issuer that had an exercise price per share that was equal to or greater than the Scheme Consideration was cancelled and ceased to be outstanding, and no Scheme Consideration was delivered in exchange for such options."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Pursuant to the terms of the Agreement, at the Effective Time each option to purchase ordinary shares of Issuer that had an exercise price per share that was equal to or greater than the Scheme Consideration was cancelled and ceased to be outstanding, and no Scheme Consideration was delivered in exchange for such options."}],"balance_after":0,"derivative":{"exercise_price":3.61,"expiration_date":"2033-12-13","underlying":"Ordinary Shares","underlying_shares":135604},"source":{"system":"sec-edgar","filing":"0001193125-25-308745","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1971543/000119312525308745/ownership.xml","form_type":"4"}},{"id":979196,"issuer":{"id":72153,"kind":"organization","name":"Mural Oncology plc","symbol":"MURA"},"owners":[{"id":72155,"kind":"person","name":"Goodman Vicki L","position":1,"cik":"0001901477","reported_name":"Goodman Vicki L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Ordinary Shares","published_at":"2025-12-05T08:45:53.000Z","date":"2025-12-05","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":84727,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Pursuant to the terms of the Transaction Agreement (the \"Agreement\"), dated August 20, 2025, by and among the Issuer, XRA 5 Corp. (\"Sub\"), a Delaware corporation and wholly-owned subsidiary of XOMA Royalty Corporation, a Nevada corporation, Sub acquired all the issued and to be issued share capital of the Issuer (the \"Acquisition\") for a cash purchase price of $2.035 per share (the \"Scheme Consideration\"), as of December 5, 2025 (the \"Effective Time\")."},{"field":"shares","element":"transactionShares","label":"F2","text":"Includes the disposition of 71,509 unvested restricted stock units (\"RSUs\"). Pursuant to the Agreement, as of the Effective Time each RSU held by the Reporting Person that was outstanding as of immediately prior to the Effective Time (whether or not vested) was automatically cancelled and converted into the right to receive an amount equal to the Scheme Consideration."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to the terms of the Transaction Agreement (the \"Agreement\"), dated August 20, 2025, by and among the Issuer, XRA 5 Corp. (\"Sub\"), a Delaware corporation and wholly-owned subsidiary of XOMA Royalty Corporation, a Nevada corporation, Sub acquired all the issued and to be issued share capital of the Issuer (the \"Acquisition\") for a cash purchase price of $2.035 per share (the \"Scheme Consideration\"), as of December 5, 2025 (the \"Effective Time\")."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Includes the disposition of 71,509 unvested restricted stock units (\"RSUs\"). Pursuant to the Agreement, as of the Effective Time each RSU held by the Reporting Person that was outstanding as of immediately prior to the Effective Time (whether or not vested) was automatically cancelled and converted into the right to receive an amount equal to the Scheme Consideration."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001193125-25-308745","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1971543/000119312525308745/ownership.xml","form_type":"4"}},{"id":1003883,"issuer":{"id":72153,"kind":"organization","name":"Mural Oncology plc","symbol":"MURA"},"owners":[{"id":72155,"kind":"person","name":"Goodman Vicki L","position":1,"cik":"0001901477","reported_name":"Goodman Vicki L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Ordinary Shares","published_at":"2025-11-10T18:30:03.000Z","date":"2025-11-10","kind":"sale","planned":true,"acquired":false,"shares":5036,"price":2.08,"value":10474.88,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares automatically sold by the Reporting Person to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the Reporting Person on December 14, 2023. The automatic sale of the Reporting Person's shares is provided for in a restricted stock unit agreement that includes a \"binding contract\" consistent with the affirmative defense to liability under Rule 10b5-1 that was entered into on December 22, 2023, and the sale does not represent a discretionary trade by the Reporting Person."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 71,509 unvested restricted stock units."}],"balance_after":84727,"source":{"system":"sec-edgar","filing":"0001193125-25-274765","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1971543/000119312525274765/ownership.xml","form_type":"4"}},{"id":1223087,"issuer":{"id":72153,"kind":"organization","name":"Mural Oncology plc","symbol":"MURA"},"owners":[{"id":72155,"kind":"person","name":"Goodman Vicki L","position":1,"cik":"0001901477","reported_name":"Goodman Vicki L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (right to buy)","published_at":"2025-03-05T16:47:53.000Z","date":"2025-03-03","kind":"grant","planned":false,"acquired":true,"shares":65000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"This option was granted on March 3, 2025. The option is scheduled to vest with respect to 25% of the underlying ordinary shares on March 1, 2026 and the remaining 75% of the underlying ordinary shares shall vest in 12 equal quarterly installments thereafter, subject to the reporting person's continued services with the Issuer."}],"balance_after":65000,"derivative":{"exercise_price":3.43,"expiration_date":"2035-03-02","underlying":"Ordinary Shares","underlying_shares":65000},"source":{"system":"sec-edgar","filing":"0000950170-25-033764","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1971543/000095017025033764/ownership.xml","form_type":"4"}},{"id":1223086,"issuer":{"id":72153,"kind":"organization","name":"Mural Oncology plc","symbol":"MURA"},"owners":[{"id":72155,"kind":"person","name":"Goodman Vicki L","position":1,"cik":"0001901477","reported_name":"Goodman Vicki L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Ordinary Shares","published_at":"2025-03-05T16:47:53.000Z","date":"2025-03-03","kind":"grant","planned":false,"acquired":true,"shares":35000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Consists of ordinary shares issuable under 35,000 restricted stock units (\"RSUs\"). Each RSU represents the right to receive one ordinary share upon vesting. The RSUs are scheduled to vest with respect to 25% of the underlying ordinary shares on each of the first four anniversaries of March 1, 2025, subject to the reporting person's continued service with the Issuer."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 54,763 unvested restricted stock units."}],"balance_after":89763,"source":{"system":"sec-edgar","filing":"0000950170-25-033764","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1971543/000095017025033764/ownership.xml","form_type":"4"}},{"id":1246826,"issuer":{"id":72153,"kind":"organization","name":"Mural Oncology plc","symbol":"MURA"},"owners":[{"id":72155,"kind":"person","name":"Goodman Vicki L","position":1,"cik":"0001901477","reported_name":"Goodman Vicki L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Ordinary Shares","published_at":"2025-02-25T16:03:08.000Z","date":"2025-02-24","kind":"sale","planned":true,"acquired":false,"shares":13186,"price":3.89,"value":51293.54,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares automatically sold by the Reporting Person pursuant to a Rule 10b5-1 trading arrangement that was entered into by the Reporting Person on October 24, 2024."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 54,763 unvested restricted stock units."}],"balance_after":54763,"source":{"system":"sec-edgar","filing":"0000950170-25-026609","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1971543/000095017025026609/ownership.xml","form_type":"4"}},{"id":1371645,"issuer":{"id":72153,"kind":"organization","name":"Mural Oncology plc","symbol":"MURA"},"owners":[{"id":72155,"kind":"person","name":"Goodman Vicki L","position":1,"cik":"0001901477","reported_name":"Goodman Vicki L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Ordinary Shares","published_at":"2024-11-08T16:02:15.000Z","date":"2024-11-07","kind":"sale","planned":true,"acquired":false,"shares":5069,"price":3.33,"value":16879.77,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares automatically sold by the Reporting Person to satisfy withholding obligations in connection with the vesting of restricted stock units granted to the Reporting Person on December 14, 2023. The automatic sale of the Reporting Person's shares is provided for in a restricted stock unit agreement that includes a \"binding contract\" consistent with the affirmative defense to liability under Rule 10b5-1 that was entered into on December 21, 2023, and the sale does not represent a discretionary trade by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.33 to $3.35. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes 54,763 unvested restricted stock units."}],"balance_after":67949,"source":{"system":"sec-edgar","filing":"0000950170-24-124041","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1971543/000095017024124041/ownership.xml","form_type":"4"}},{"id":1707637,"issuer":{"id":72153,"kind":"organization","name":"Mural Oncology plc","symbol":"MURA"},"owners":[{"id":72155,"kind":"person","name":"Goodman Vicki L","position":1,"cik":"0001901477","reported_name":"Goodman Vicki L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (right to buy)","published_at":"2023-12-18T16:30:50.000Z","date":"2023-12-14","kind":"grant","planned":false,"acquired":true,"shares":135604,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option was granted on December 14, 2023. The option is scheduled to vest with respect to 25% of the underlying ordinary shares on November 6, 2024 and the remaining 75% of the underlying ordinary shares shall vest in 12 equal quarterly installments thereafter, subject to the reporting person's continued service with the Issuer."}],"balance_after":135604,"derivative":{"exercise_price":3.61,"expiration_date":"2033-12-13","underlying":"Ordinary Shares","underlying_shares":135604},"source":{"system":"sec-edgar","filing":"0000950170-23-071113","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1971543/000095017023071113/ownership.xml","form_type":"4"}},{"id":1707636,"issuer":{"id":72153,"kind":"organization","name":"Mural Oncology plc","symbol":"MURA"},"owners":[{"id":72155,"kind":"person","name":"Goodman Vicki L","position":1,"cik":"0001901477","reported_name":"Goodman Vicki L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Ordinary Shares","published_at":"2023-12-18T16:30:50.000Z","date":"2023-12-14","kind":"grant","planned":false,"acquired":true,"shares":73018,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Consists of ordinary shares issuable under 73,018 restricted stock units (\"RSUs\"). Each RSU represents the right to receive one ordinary share upon vesting. The RSUs are scheduled to vest with respect to 25% of the underlying ordinary shares on each of the first four anniversaries of November 6, 2023, subject to the reporting person's continued service with the Issuer."}],"balance_after":73018,"source":{"system":"sec-edgar","filing":"0000950170-23-071113","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1971543/000095017023071113/ownership.xml","form_type":"4"}},{"id":1925807,"issuer":{"id":3386,"kind":"organization","name":"EXELIXIS, INC."},"owners":[{"id":72155,"kind":"person","name":"Goodman Vicki L","position":1,"cik":"0001901477","reported_name":"Goodman Vicki L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Prod Dev & Med Aff &CMO"}}],"security":"Common Stock","published_at":"2023-04-06T00:24:18.000Z","date":"2023-04-03","kind":"grant","planned":false,"acquired":true,"shares":82566,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Represents shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units. Each restricted stock unit is the economic equivalent of one share of Exelixis, Inc. common stock."},{"field":"date","element":"transactionDate","label":"F2","text":"The restricted stock units were granted to the Reporting Person on the Transaction Date pursuant to the Exelixis, Inc. 2017 Equity Incentive Plan. The restricted stock units will vest as to 1/4th of the original number of shares subject to the restricted stock unit award on May 15, 2024 and thereafter as to 1/4th of the original number of shares subject to the restricted stock unit award on each May 15th until fully vested."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes 246,383 shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units."}],"balance_after":307654,"source":{"system":"sec-edgar","filing":"0000939767-23-000037","document":"wf-form4_168074064086550.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/939767/000093976723000037/wf-form4_168074064086550.xml","form_type":"4"}},{"id":2008994,"issuer":{"id":3386,"kind":"organization","name":"EXELIXIS, INC."},"owners":[{"id":72155,"kind":"person","name":"Goodman Vicki L","position":1,"cik":"0001901477","reported_name":"Goodman Vicki L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Prod Dev & Med Aff &CMO"}}],"security":"Common Stock","published_at":"2023-02-18T02:38:05.000Z","date":"2023-02-15","kind":"tax_withholding","acquired":false,"shares":17299,"price":18.08,"value":312765.92,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Shares withheld by Exelixis, Inc. to satisfy taxes payable in connection with the vesting of restricted stock units awarded January 4, 2022."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 163,817 shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units."}],"balance_after":225088,"source":{"system":"sec-edgar","filing":"0000939767-23-000022","document":"wf-form4_167668786613786.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/939767/000093976723000022/wf-form4_167668786613786.xml","form_type":"4"}},{"id":2442072,"issuer":{"id":3386,"kind":"organization","name":"EXELIXIS, INC."},"owners":[{"id":72155,"kind":"person","name":"Goodman Vicki L","position":1,"cik":"0001901477","reported_name":"Goodman Vicki L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Prod Dev & Med Aff &CMO"}}],"security":"Common Stock","published_at":"2022-01-07T01:02:52.000Z","date":"2022-01-04","kind":"tax_withholding","acquired":false,"shares":7613,"price":19.18,"value":146017.34,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F4","text":"Shares withheld by Exelixis, Inc. to satisfy taxes payable in connection with the vesting of restricted stock units awarded on the Transaction Date."}],"balance_after":242387,"source":{"system":"sec-edgar","filing":"0000939767-22-000004","document":"wf-form4_164151735117017.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/939767/000093976722000004/wf-form4_164151735117017.xml","form_type":"4"}},{"id":2442071,"issuer":{"id":3386,"kind":"organization","name":"EXELIXIS, INC."},"owners":[{"id":72155,"kind":"person","name":"Goodman Vicki L","position":1,"cik":"0001901477","reported_name":"Goodman Vicki L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Prod Dev & Med Aff &CMO"}}],"security":"Common Stock","published_at":"2022-01-07T01:02:52.000Z","date":"2022-01-04","kind":"grant","acquired":true,"shares":250000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Represents shares of Exelixis, Inc. common stock issued to the Reporting Person upon vesting of restricted stock units. Each restricted stock unit is the economic equivalent of one share of Exelixis, Inc. common stock."},{"field":"date","element":"transactionDate","label":"F2","text":"The restricted stock units were granted to the Reporting Person on the Transaction Date pursuant to the Exelixis, Inc. 2017 Equity Incentive Plan. The restricted stock units will vest as follows: 26,315 shares subject to the restricted stock unit award vested on the Transaction Date; 59,868 shares subject to the restricted stock unit award will vest on February 15, 2023; 59,869 shares subject to the restricted stock unit award will vest on February 15, 2024; and 51,974 shares subject to the restricted stock unit award will vest on each of February 15, 2025 and February 15, 2026."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes 223,685 shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units."}],"balance_after":250000,"source":{"system":"sec-edgar","filing":"0000939767-22-000004","document":"wf-form4_164151735117017.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/939767/000093976722000004/wf-form4_164151735117017.xml","form_type":"4"}}]}